Malin Corp PLC - Dublin-based investor in life sciences companies - Notes announcement from Nasdaq-listed Poseida Therapeutics Inc of its entry into a strategic collaboration and licence agreement with Roche Holding AG, for the development of allogeneic CAR-T therapies directed towards hematologic malignancies.

Poseida will receive $110 million upfront, and can fain an additional $110 million in near-term milestones and other payments.

Current stock price: €4.15

12-month change: down 38%

Copyright 2022 Alliance News Limited. All Rights Reserved.